Good news for us- this is a huge under reported market so if we can get this indication it can mean continued jobs for us! Cosentyx still kicking our ass but we are coming for them! Just my opinion but we should have spent the money on formulary coverage instead of commercials- we give more drug away then we fill! https://endpts.com/eli-lilly-touts-phiii-success-for-taltz-as-rival-novartis-stays-well-out-front-in-crowded-immunology-race/
